Synoste develops smart, patient-friendly solutions for bone lengthening and bone-deformation correction using a patented technology platform. Its platform underpins treatments for congenital, trauma- and tumour-related limb discrepancies, adult and paediatric deformities, and craniomaxillofacial deformations. The company is led by Managing Director and co-founder Harri Hallila and has locations in Helsinki, Finland and Düsseldorf, Germany. Synoste intends to use newly raised funds to start clinical investigations and to develop new clinical applications. The company has secured investment from several strategic and VC investors to support clinical and product development. Total funding to date is reported at €10m. Synoste is an Espoo, Finland medical device company developing patient-friendly implants for the correction of skeletal deformations. Its proprietary technology, developed at Aalto University and ORTON Orthopaedic Hospital, is positioned as a platform for long and short bone, spinal, and craniomaxillofacial applications. The company plans to use capital to fund clinical trials needed for regulatory approval (CE Mark) to enable sale of its first product in Europe. Synoste raised €2.2M in Series A financing and also received a €1.0M European Eurostars grant. The Series A funding came from existing investors High‑Tech Gründerfonds (HTGF), Finnvera, Lifeline Ventures, Mectalent Oy and existing business angels, plus new investors Metsola Ventures and Mr Petri Pöyhönen. The company is led by CEO and co-founder Harri Hallila and Director of Business Development Michael Piccirillo. Synoste is developing implantable devices for the limb lengthening market based on a proprietary technology platform developed at Aalto University and ORTON Orthopaedic Hospital. The devices are designed for routine implantation and allow correct extraction via a magnetic field using a home care unit, reducing the need for daily hospital visits. The company is led by CEO and co‑founder Harri Hallila and is based in Helsinki, Finland and Düsseldorf, Germany. Synoste closed an up to €2.8m funding round to advance its program. It has raised a €0.8m seed tranche that can be increased by up to €1.2m upon reaching certain milestones. The company intends to use the funds to finalize its prototype and advance into pre‑clinical development.

Total raised

$11M

Funding rounds

4

Latest round

Equity

Latest activity

Oct 2018